Bausch Health Companies Inc.

NYSE:BHC

Drug Manufacturers - Specialty & Generic

Healthcare
$8.73 -2.21%

-$0.11 today

Market cap
$3.27B
Beta
0.41
P/E (TTM)
-1.5
EPS (TTM)
-$3.19
52W Low $4.57High $8.69

Volume 6.83M

Average 1.70M

BHC Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Bausch Health Companies Inc.NYSE: BHC

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income grows in line with its trailing trend

Q2 FY2026 operating income of $775M rose 69.6% year over year, in line with the +69.9% change in trailing-twelve-month operating income. Sequentially, it rose 48.8% from the prior quarter. Over 3 fiscal years it compounded at +68.8% a year.

Context

  • Operating income amounted to 21.3% of revenue in FY2025, up 5.2 pp from a year earlier.
  • Operating income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 4 analysts of $4.27B (+95.3%) for the fiscal year ending Dec 2026, a step up from the +41.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$775M+48.8% QoQ
Last fiscal yearDec 2025
$2.19B+41.3% YoY
LTMJun 2026
$2.76B+69.9% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+69.6%+74.3%+4.7 pp
1 year+41.3%+95.3%+54.0 pp
3-year CAGR+68.8%+14.2%-54.7 pp
5-year CAGR+8.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
2.19B USD
Year-over-year change
+41.3%
4-year CAGR
+48.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How BHC compares with its peers on the latest reported figures

  • BHC's LTM Jun 2026 operating income of $2.76B is the highest of the 11 companies compared; the peer median is $169.3M.
  • Its year-over-year change of +69.9% is the 4th highest of 11, against a peer median of +15.5%.
  • Operating income amounts to 25.4% of revenue for BHC, versus a peer median of 13.8%.
BHC Competitors Peer median
Operating Income for BHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$2.76B +69.9%+68.8%25.4%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$395.54M +22.3%+9.0%16.9%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$267.64M +15.7%+36.3%44.8%
HAEHaemonetics CorporationLTM Jun 2026$245.74M +13.7%+15.7%18.2%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$216M +125.2%—5.9%
PRGOPerrigo Company plcLTM Jun 2026$215M -25.1%+63.3%5.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$123.61M +1811.6%—13.4%
ALVOAlvotechLTM Mar 2026$77.22M -40.0%—13.8%
HCMHUTCHMED (China) LimitedLTM Jun 2025-$19.7M +83.7%—3.3%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$370.79M -82.6%——
BEAMBeam Therapeutics Inc.LTM Jun 2026-$378.02M +15.2%—242.3%
Peer median (excluding BHC) $169.3M+15.5%+26.0%13.8%

Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue8.43B8.12B8.76B9.63B10.27B
Cost of Revenue2.39B2.36B2.56B2.78B3.01B
Gross Profit6.04B5.76B6.2B6.84B7.25B
Gross Margin71.6%70.9%70.8%71.1%70.7%
Research & Development473M530M604M634M629M
Selling, General & Admin2.49B2.53B2.9B3.28B3.44B
Operating Expenses5.59B5.31B5.24B5.3B5.07B
Depreciation & Amortization1.55B1.39B1.26B1.27B1.21B
EBITDA3.26B2.88B2.89B3.13B3.18B
EBITDA Margin38.7%35.4%32.9%32.6%31.0%
Operating Income450M454M963M1.55B2.19B
Operating Margin5.3%5.6%11.0%16.1%21.3%
Interest Income7M14M26M33M48M
Interest Expense1.43B1.46B1.33B1.39B1.6B
Other Income / Expenses(1.47B)(583M)(1.35B)(1.38B)(1.82B)
Income Before Tax(1.02B)(129M)(390M)167M367M
Pre-Tax Margin-12.1%-1.6%-4.5%1.7%3.6%
Income Tax Expense(87M)83M221M239M247M
Net Income(948M)(225M)(592M)(46M)157M
Net Margin-11.2%-2.8%-6.8%-0.5%1.5%
EPS (Basic)(2.61)(0.62)(1.62)(0.13)0.43
EPS (Diluted)(2.61)(0.62)(1.62)(0.13)0.43
Weighted Avg Shares358.9M362M364.9M368M370.9M
Weighted Avg Shares (Diluted)358.9M362M364.9M368M375M

Bausch Health Companies Inc.

NYSE:BHC

Intrinsic Alpha fair value

Locked

Current Price

$8.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.